The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
10.3346/jkms.2017.32.2.249
- Author:
Sang Ryol RYU
1
;
Sue K PARK
;
Ji Yong JUNG
;
Yeong Hoon KIM
;
Yun Kyu OH
;
Tae Hyun YOO
;
Suah SUNG
Author Information
1. Department of Internal Medicine, Yeosu Chonnam Hospital, Yeosu, Korea.
- Publication Type:Original Article
- Keywords:
Anemia;
Chronic Kidney Disease;
Korean
- MeSH:
Anemia*;
Body Mass Index;
Calcium;
Cohort Studies*;
Diabetic Nephropathies;
Female;
Hematinics;
Humans;
Iron;
Korea;
Leukocyte Count;
Male;
National Health Programs;
Phosphorus;
Prevalence*;
Renal Insufficiency, Chronic*;
Risk Factors;
Serum Albumin;
Smoke;
Smoking
- From:Journal of Korean Medical Science
2017;32(2):249-256
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anemia is a common and significant complication of chronic kidney disease (CKD). However, its prevalence and current management status has not been studied thoroughly in Korea. We examined the prevalence of anemia, its association with clinical and laboratory factors, and utilization of iron agents and erythropoiesis stimulating agents using the baseline data from the large-scale CKD cohort in Korea. We defined anemia when hemoglobin level was lower than 13.0 g/dL in males and 12.0 g/dL in females, or received by erythropoiesis stimulating agents. Overall prevalence of anemia was 45.0% among 2,198 non-dialysis CKD patients from stage 1 to 5. Diabetic nephropathy (DN) as a cause, CKD stages, body mass index (BMI), smoking, leukocyte count, serum albumin, iron markers, calcium, and phosphorus concentration were identified as independent risk factors for anemia. Considering the current coverage of Korean National Health Insurance System, only 7.9% among applicable patients were managed by intravenous iron agents, and 42.7% were managed by erythropoiesis stimulating agents.
